Carolynne J. Vaizey
Research Subjects
Carolynne J. Vaizey has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
T. C. Dudding
Departments of Physiology
7 shared publications- James Hollingshead
Watford General Hospital , Watford, United Kingdom
5 shared publications M. A. Kamm
St Mark’s Hospital, London, UK
5 shared publicationsR. J. Nicholls
Colorectal Surgery, St Mark’s Hospital, North West London Hospitals NHS Trust, Harrow, UK
5 shared publications- Yasuko Maeda
Department of Surgery Queen Elizabeth University Hospital Glasgow UK
5 shared publications - David Parés
Servicio de Cirugía General y Digestiva, Hospital Germans Trias i Pujol, Universitat Autònoma de Barcelona, Spain
3 shared publications
Latest Publications
- Open Access
- 6 December 2012
- Published by Springer Nature
Study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulae
- 6 December 2012
- Published by Springer Nature
Open AccessStudy of immunological factors in non-inflammatory bowel disease enterocutaneous fistulae
- Open Access
- 5 December 2012
- Published by Springer Nature
Prospective randomised controlled trial to assess the effect of colonoscopy patient information leaflets on patient knowledge and anxiety
- 5 December 2012
- Published by Springer Nature
Open AccessProspective randomised controlled trial to assess the effect of colonoscopy patient information leaflets on patient knowledge and anxiety
- 7 December 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (1) , 98-103
A new minimally invasive technique for pudendal nerve stimulation1
Pudendal nerve stimulation (PNS), which is an alternative to sacral nerve stimulation, requires neurophysiological confirmation of correct siting of the electrode. We describe a modification of the existing technique where placement is assisted by guidance to the ischial spine by a finger introduced per anum. Cadaveric dissection was carried out to confirm the accuracy of this new approach. The surface marking of the ischial spine is marked. A stimulating needle electrode inserted through a skin incision at this point, is advanced towards the ischial spine using a finger introduced per anum as a guide. Once effective stimulation of the pudendal nerve is confirmed by observed and palpated contraction of the anal musculature, a permanent stimulating electrode is inserted and the position confirmed by radiological screening. Using cadaveric studies, the correct surface markings for needle placement were confirmed. This technique was then applied successfully for in vivo insertion of the needle electrode in 20 patients with bowel dysfunction, with only one lead displacement occurring over a mean follow-up period of 12 months. Finger-guided assistance of PNS electrode insertion is simple and reproducible without requiring neurophysiological confirmation of nerve stimulation to ensure correct lead location.
- 7 December 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (1) , 98-103
A new minimally invasive technique for pudendal nerve stimulation1
Pudendal nerve stimulation (PNS), which is an alternative to sacral nerve stimulation, requires neurophysiological confirmation of correct siting of the electrode. We describe a modification of the existing technique where placement is assisted by guidance to the ischial spine by a finger introduced per anum. Cadaveric dissection was carried out to confirm the accuracy of this new approach. The surface marking of the ischial spine is marked. A stimulating needle electrode inserted through a skin incision at this point, is advanced towards the ischial spine using a finger introduced per anum as a guide. Once effective stimulation of the pudendal nerve is confirmed by observed and palpated contraction of the anal musculature, a permanent stimulating electrode is inserted and the position confirmed by radiological screening. Using cadaveric studies, the correct surface markings for needle placement were confirmed. This technique was then applied successfully for in vivo insertion of the needle electrode in 20 patients with bowel dysfunction, with only one lead displacement occurring over a mean follow-up period of 12 months. Finger-guided assistance of PNS electrode insertion is simple and reproducible without requiring neurophysiological confirmation of nerve stimulation to ensure correct lead location.
- 18 July 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (8) , e196-e202
Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications
A knowledge of the principles of neurostimulation is essential to achieve optimal efficacy and minimize adverse effects. The aim of this article was to review the current evidence regarding device programming in the management of patients having sacral nerve stimulation (SNS) for faecal incontinence. A Medline search was performed including the keywords and/or MeSH headings of sacral nerve stimulation, neuromodulation, artificial pacemaker, faecal incontinence, programming, adverse effects and complications. Further studies were identified by cross-referencing from relevant articles and by appraisal of recent peer-reviewed conference abstracts and proceedings. Neurostimulator programming is an important component of SNS. Efficacy can be improved or restored with reprogramming. Adverse stimulation is often reversible, and nonstimulation-related complications are correctable. A total loss of efficacy can be explained in over one-half of patients. An improved outcome of SNS can be achieved by selecting the best possible stimulation parameters individualized to each patient. Further research into the optimal settings is needed.
- 18 July 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (8) , e196-e202
Sacral nerve stimulation for faecal incontinence: optimizing outcome and managing complications
A knowledge of the principles of neurostimulation is essential to achieve optimal efficacy and minimize adverse effects. The aim of this article was to review the current evidence regarding device programming in the management of patients having sacral nerve stimulation (SNS) for faecal incontinence. A Medline search was performed including the keywords and/or MeSH headings of sacral nerve stimulation, neuromodulation, artificial pacemaker, faecal incontinence, programming, adverse effects and complications. Further studies were identified by cross-referencing from relevant articles and by appraisal of recent peer-reviewed conference abstracts and proceedings. Neurostimulator programming is an important component of SNS. Efficacy can be improved or restored with reprogramming. Adverse stimulation is often reversible, and nonstimulation-related complications are correctable. A total loss of efficacy can be explained in over one-half of patients. An improved outcome of SNS can be achieved by selecting the best possible stimulation parameters individualized to each patient. Further research into the optimal settings is needed.
- 18 July 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (8) , e187-e195
Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique
Faecal incontinence is estimated to affect between 2 and 3% of Western adult populations. In recent years sacral nerve stimulation has become an important treatment modality, often as the first-line surgical therapy. The aim of this article was to review the current evidence regarding patient selection and surgical technique and to evaluate the logistics of providing a neurostimulation service. A Medline search was performed including the keywords and/or MeSH headings of sacral nerve stimulation, neuromodulation, artificial pacemaker, faecal incontinence, patient selection, predictive factors and anal canal. Further studies were identified by cross-referencing from relevant articles and by appraisal of recent peer-reviewed conference abstracts and proceedings. Despite the success of sacral nerve stimulation for several pathophysiological causes of incontinence, case selection is of paramount importance. Sacral nerve stimulation should not be offered outside a multidisciplinary pelvic floor unit. Temporary evaluation using diary cards can lead to false positive and negative results. Adherence to a meticulous surgical technique, using low amplitude stimulation to guide lead placement, provides optimal clinical outcome. The short-term outcome of sacral nerve stimulation is dependent on patient factors and operative technique. Despite this, specific preoperative predictive factors of treatment success have yet to be identified.
- 18 July 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (8) , e187-e195
Sacral nerve stimulation for faecal incontinence: patient selection, service provision and operative technique
Faecal incontinence is estimated to affect between 2 and 3% of Western adult populations. In recent years sacral nerve stimulation has become an important treatment modality, often as the first-line surgical therapy. The aim of this article was to review the current evidence regarding patient selection and surgical technique and to evaluate the logistics of providing a neurostimulation service. A Medline search was performed including the keywords and/or MeSH headings of sacral nerve stimulation, neuromodulation, artificial pacemaker, faecal incontinence, patient selection, predictive factors and anal canal. Further studies were identified by cross-referencing from relevant articles and by appraisal of recent peer-reviewed conference abstracts and proceedings. Despite the success of sacral nerve stimulation for several pathophysiological causes of incontinence, case selection is of paramount importance. Sacral nerve stimulation should not be offered outside a multidisciplinary pelvic floor unit. Temporary evaluation using diary cards can lead to false positive and negative results. Adherence to a meticulous surgical technique, using low amplitude stimulation to guide lead placement, provides optimal clinical outcome. The short-term outcome of sacral nerve stimulation is dependent on patient factors and operative technique. Despite this, specific preoperative predictive factors of treatment success have yet to be identified.
- 31 May 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (9) , e293-e296
Long‐term outcome of the use of botulinum toxin injection for functional anal pain
Aim Anal pain may occur in the absence of demonstrable anal pathology. Spasm of the sphincter muscles has been suggested as a cause in some patients. We aimed to assess the effectiveness of injection of botulinum toxin in treating this condition.Method Patients who had injection of botulinum toxin over a 3‐year period were identified retrospectively. Patients were excluded if anal fissure or other organic pathology was found to account for their symptoms on examination under anaesthetic. Long‐term outcome was assessed at a minimum 3‐year post‐procedure telephone follow up.Results Fourteen (eight male) patients were identified, of median age 50 years. Botulinum toxin (20–200 u) was injected into the internal sphincter. Seven of the 14 patients reported significant improvement in symptoms at 3 months. Seven were available for a structured telephone review at a median of 59 (42–68) months. The four patients who had benefited from the injection had remained asymptomatic.Conclusion Injection of botulinum toxin into the internal anal sphincter has a role in alleviating symptoms in a small proportion of patients with functional anal pain.
- 31 May 2011
- Published by Wiley in Colorectal Disease
- Vol. 13 (9) , e293-e296
Long‐term outcome of the use of botulinum toxin injection for functional anal pain
Aim Anal pain may occur in the absence of demonstrable anal pathology. Spasm of the sphincter muscles has been suggested as a cause in some patients. We aimed to assess the effectiveness of injection of botulinum toxin in treating this condition.Method Patients who had injection of botulinum toxin over a 3‐year period were identified retrospectively. Patients were excluded if anal fissure or other organic pathology was found to account for their symptoms on examination under anaesthetic. Long‐term outcome was assessed at a minimum 3‐year post‐procedure telephone follow up.Results Fourteen (eight male) patients were identified, of median age 50 years. Botulinum toxin (20–200 u) was injected into the internal sphincter. Seven of the 14 patients reported significant improvement in symptoms at 3 months. Seven were available for a structured telephone review at a median of 59 (42–68) months. The four patients who had benefited from the injection had remained asymptomatic.Conclusion Injection of botulinum toxin into the internal anal sphincter has a role in alleviating symptoms in a small proportion of patients with functional anal pain.
- Open Access
- 27 May 2011
- Published by Springer Nature in BMC Surgery
- Vol. 11 (1) , 12
Prospective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas
Enterocutaneous fistulas (ECF) are debilitating and usually result following complex abdominal surgery. While there is an association with inflammatory bowel disease (IBD), a large number of fistulas occur after surgery not related to IBD. The consequences of ECF include short bowel syndrome and the need for long term parenteral nutrition.
- 27 May 2011
- Published by Springer Nature in BMC Surgery
- Vol. 11 (1) , 12
Open AccessProspective study of immunological factors in non-inflammatory bowel disease enterocutaneous fistulas
Enterocutaneous fistulas (ECF) are debilitating and usually result following complex abdominal surgery. While there is an association with inflammatory bowel disease (IBD), a large number of fistulas occur after surgery not related to IBD. The consequences of ECF include short bowel syndrome and the need for long term parenteral nutrition.
- Open Access
A prospective single blinded placebo controlled study into the role of percutaneous and transcutaneous tibial nerve stimulation for faecal incontinence
Introduction Posterior tibial nerve stimulation (PTNS) is a safe and effective treatment1 2 for faecal incontinence (FI) but it is not known whether percutaneous or transcutaneous routes of stimulation are better. The efficacy of PTNS was assessed in a prospective randomised placebo-controlled trial. Methods Patients who had failed conservative treatment for FI were blinded and randomised to one of the three forms of stimulation: Group 1: Percutaneous, Group 2: Transcutaneous, Group 3: Sham transcutaneous. All patients had a 2 week baseline assessment of symptoms. Patients in Group 1 and Group 2 received 30 min sessions of PTNS twice weekly for 6 weeks. In Group 3 transcutaneous electrodes were placed but no stimulation was delivered. All patients were assessed blind at 6 weeks; unblinded and followed up after a further 1 month to assess symptoms. Treatment success was defined as > 50% reduction in weekly episodes of faecal incontinence following the 6 weeks of PTNS when compared to baseline symptoms. Results Thirty patients (M:F 2:28) were included in the study. Nine (82%) of 11 patients in Group 1, 5 (45%) of 11 in Group 2 and 1 (12.5%) of 8 in Group 3 had a more than 50% reduction in weekly episodes of FI at the end of the 6 week study phase (table 1). Patients also showed an improvement in their ability to defer defecation and in the St Mark's Continence scores pre and post treatment. PWE-071 The improved continence observed in the above patients of all the 3 groups was sustained at the 1 month post study follow-up. There were no complications observed in any patient. Conclusion This study demonstrates the efficacy of PTNS as a treatment option for FI in the short term.
Open AccessA prospective single blinded placebo controlled study into the role of percutaneous and transcutaneous tibial nerve stimulation for faecal incontinence
Introduction Posterior tibial nerve stimulation (PTNS) is a safe and effective treatment1 2 for faecal incontinence (FI) but it is not known whether percutaneous or transcutaneous routes of stimulation are better. The efficacy of PTNS was assessed in a prospective randomised placebo-controlled trial. Methods Patients who had failed conservative treatment for FI were blinded and randomised to one of the three forms of stimulation: Group 1: Percutaneous, Group 2: Transcutaneous, Group 3: Sham transcutaneous. All patients had a 2 week baseline assessment of symptoms. Patients in Group 1 and Group 2 received 30 min sessions of PTNS twice weekly for 6 weeks. In Group 3 transcutaneous electrodes were placed but no stimulation was delivered. All patients were assessed blind at 6 weeks; unblinded and followed up after a further 1 month to assess symptoms. Treatment success was defined as > 50% reduction in weekly episodes of faecal incontinence following the 6 weeks of PTNS when compared to baseline symptoms. Results Thirty patients (M:F 2:28) were included in the study. Nine (82%) of 11 patients in Group 1, 5 (45%) of 11 in Group 2 and 1 (12.5%) of 8 in Group 3 had a more than 50% reduction in weekly episodes of FI at the end of the 6 week study phase (table 1). Patients also showed an improvement in their ability to defer defecation and in the St Mark's Continence scores pre and post treatment. PWE-071 The improved continence observed in the above patients of all the 3 groups was sustained at the 1 month post study follow-up. There were no complications observed in any patient. Conclusion This study demonstrates the efficacy of PTNS as a treatment option for FI in the short term.
- 10 January 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (2) , 200-204
Sacral nerve stimulation in the elderly
Aim Increasing life expectancy will increase the number of elderly patients with faecal incontinence. The study aimed to assess the safety and efficacy of sacral nerve stimulation (SNS) in patients over the age of 65 years.Method Patients aged over 65 years, who underwent temporary SNS from 1996 for faecal incontinence unresponsive to conservative treatment, were followed prospectively.Results Between January 1996 and December 2009, 30 patients [mean age 69.3 years (SD, 3.4)] underwent temporary SNS. Twenty‐three (77%) had a >50% improvement in the St Mark’s Continence Score and progressed to permanent SNS implantation. Their mean (±SD) score increased from 19 (3.2) at baseline to 8 (3.4) during temporary SNS and to 9 (3.4) 3 months after permanent SNS and 10 (3.7) at the latest median follow up (IQR) of 44 (20–150) months. The corresponding values at the same intervals for urgency [mean (±SD) min] were 1 (1.4), 8 (5.2), 8 (5) and 8 (5.4) and for incontinence episodes per 2 weeks [median (±IQR)] were 10 (7–14), 1 (0–5), 2 (0–5) and 0 (0–6).Conclusion SNS is an effective treatment for faecal incontinence in patients over 65 years.
- 10 January 2011
- Published by Wiley in Colorectal Disease
- Vol. 14 (2) , 200-204
Sacral nerve stimulation in the elderly
Aim Increasing life expectancy will increase the number of elderly patients with faecal incontinence. The study aimed to assess the safety and efficacy of sacral nerve stimulation (SNS) in patients over the age of 65 years.Method Patients aged over 65 years, who underwent temporary SNS from 1996 for faecal incontinence unresponsive to conservative treatment, were followed prospectively.Results Between January 1996 and December 2009, 30 patients [mean age 69.3 years (SD, 3.4)] underwent temporary SNS. Twenty‐three (77%) had a >50% improvement in the St Mark’s Continence Score and progressed to permanent SNS implantation. Their mean (±SD) score increased from 19 (3.2) at baseline to 8 (3.4) during temporary SNS and to 9 (3.4) 3 months after permanent SNS and 10 (3.7) at the latest median follow up (IQR) of 44 (20–150) months. The corresponding values at the same intervals for urgency [mean (±SD) min] were 1 (1.4), 8 (5.2), 8 (5) and 8 (5.4) and for incontinence episodes per 2 weeks [median (±IQR)] were 10 (7–14), 1 (0–5), 2 (0–5) and 0 (0–6).Conclusion SNS is an effective treatment for faecal incontinence in patients over 65 years.
- 16 August 2010
- Published by Wiley in Colorectal Disease
- Vol. 13 (9) , 1030-1034
Sacral nerve stimulation for faecal incontinence: results from a single centre over a 10‐year period
Aim Sacral nerve stimulation (SNS) is considered a first‐line surgical treatment option for faecal incontinence. There is little information on long‐term results. The results of SNS for faecal incontinence performed at a single centre over a 10‐year period are reported.Method A cohort analysis of consecutive patients treated with SNS for faecal incontinence over a 10‐year period was carried out. Data were collected prospectively using bowel habit diaries and St Mark’s and Cleveland Clinic incontinence scores. Treatment success was defined as a > 50% reduction in episodes of faecal incontinence compared with baseline.Results Temporary SNS was performed in 118 patients, and 91 (77%) were considered suitable for chronic stimulation. The median period of follow up was 22 (1–138) months. Seventy patients were followed for 1 year with success in 63 (90%). Of 18 patients followed for 5 years, 15 (83%) reported continued success, 11 (61%) maintained full efficacy, 4 (22%) reported some loss, and 3 (17%) reported complete loss. Three patients with a 10‐year follow up had no loss in efficacy. Overall, complete loss of efficacy was observed in 14 (16%) patients at a median of 11.5 months following implantation. A further 5 (6%) patients showed deterioration with time. In 9 (47%), no reason for the deterioration in symptoms could be identified.Conclusions SNS can be effective for up to 10 years. Some patients experience deterioration in symptoms over time. The reasons for this are often not evident.
- 16 August 2010
- Published by Wiley in Colorectal Disease
- Vol. 13 (9) , 1030-1034
Sacral nerve stimulation for faecal incontinence: results from a single centre over a 10‐year period
Aim Sacral nerve stimulation (SNS) is considered a first‐line surgical treatment option for faecal incontinence. There is little information on long‐term results. The results of SNS for faecal incontinence performed at a single centre over a 10‐year period are reported.Method A cohort analysis of consecutive patients treated with SNS for faecal incontinence over a 10‐year period was carried out. Data were collected prospectively using bowel habit diaries and St Mark’s and Cleveland Clinic incontinence scores. Treatment success was defined as a > 50% reduction in episodes of faecal incontinence compared with baseline.Results Temporary SNS was performed in 118 patients, and 91 (77%) were considered suitable for chronic stimulation. The median period of follow up was 22 (1–138) months. Seventy patients were followed for 1 year with success in 63 (90%). Of 18 patients followed for 5 years, 15 (83%) reported continued success, 11 (61%) maintained full efficacy, 4 (22%) reported some loss, and 3 (17%) reported complete loss. Three patients with a 10‐year follow up had no loss in efficacy. Overall, complete loss of efficacy was observed in 14 (16%) patients at a median of 11.5 months following implantation. A further 5 (6%) patients showed deterioration with time. In 9 (47%), no reason for the deterioration in symptoms could be identified.Conclusions SNS can be effective for up to 10 years. Some patients experience deterioration in symptoms over time. The reasons for this are often not evident.